Residency · Residency · Pediatrics

Well-Child Surveillance and Developmental Screening

Overview

Well-child visits are the cornerstone of pediatric preventive care. The AAP Bright Futures guidelines define the periodicity schedule and content for health supervision visits. Developmental surveillance occurs at every visit, with formal screening performed at designated ages. The goal is early identification of developmental delays to enable early intervention during critical windows of brain plasticity. One in six children (17%) has a developmental disability, yet fewer than half are identified before school entry without systematic screening.

Bright Futures Periodicity Schedule

Visit Schedule

The schedule begins with a prenatal visit to establish the relationship and provide counseling. The first postnatal visit occurs within 3-5 days of birth or within 48-72 hours of hospital discharge. During infancy, visits are scheduled at 1, 2, 4, 6, 9, 12, 15, 18, 24, and 30 months. Early childhood visits occur at ages 3, 4, and 5 years (kindergarten entry). Middle childhood visits are annual from 6-10 years. Adolescent visits continue annually from 11-21 years. Each visit includes measurements, developmental surveillance, anticipatory guidance, indicated screening tests, and immunizations.

Components of Each Visit

Every visit includes a physical examination with growth parameters and age-specific exam focus, developmental surveillance through ongoing monitoring of milestones, formal developmental screening with validated tools at designated ages, behavioral and mental health screening at defined intervals, anticipatory guidance covering nutrition, safety, sleep, media use, and dental health, immunizations per the CDC schedule, and age-appropriate screening tests for vision, hearing, anemia, lead, lipids, and STIs.

Developmental Milestones by Age

Key Milestones (Selected)

At 2 months, infants demonstrate a social smile, follow past midline, lift the head when prone, and coo. By 4 months, they laugh, reach for objects, roll front to back, and bear weight on legs. At 6 months, babbling begins, objects are transferred hand to hand, sitting with support is achieved, and stranger awareness emerges. By 9 months, the pincer grasp is emerging, pulling to stand occurs, "mama/dada" is used nonspecifically, and the child understands "no."

At 12 months, 1-3 words are spoken, walking with one hand held is achieved, the pincer grasp is mature, and the child waves bye-bye. By 15 months, vocabulary reaches 3-5 words, independent walking occurs, 2 blocks are stacked, and the child drinks from a cup. At 18 months, 10-25 words are used, the child points to show interest, scribbles, stacks 3-4 blocks, and follows 1-step commands. By 24 months, vocabulary exceeds 50 words, 2-word phrases emerge, the child kicks a ball, stacks 6 blocks, and engages in parallel play.

At 3 years, children use 3-word sentences, ride a tricycle, copy a circle, know their full name, and begin group play. By 4 years, they tell stories, hop on one foot, copy a cross, and count to 4. At 5 years, children count to 10, skip, copy a triangle, dress independently, and understand rules of games.

Red Flags Requiring Immediate Evaluation

Certain findings demand immediate referral rather than watchful waiting: no babbling by 12 months, no words by 16 months, no 2-word phrases by 24 months, loss of previously acquired skills at any age (regression), no pointing or gesturing by 12 months, poor eye contact or lack of social reciprocity, and not walking by 18 months.

<image>Visual timeline of key developmental milestones from birth to 5 years organized by domain (gross motor, fine motor, language, social-emotional) with red flag indicators for each age period that should prompt further evaluation</image>

Validated Screening Tools

Developmental Screening (Recommended at 9, 18, and 30 Months)

The ASQ-3 (Ages and Stages Questionnaire, 3rd Edition) is a parent-completed tool with 30 items across five domains: communication, gross motor, fine motor, problem-solving, and personal-social. Age-specific forms are available from 1-66 months in multiple languages. Sensitivity ranges from 70-90% with specificity of 76-91%. Cutoff scores identify children needing further evaluation.

The PEDS (Parents' Evaluation of Developmental Status) is a 10-item parent-completed screener that identifies parental concerns predictive of developmental issues. It can be administered rapidly in 2-5 minutes.

Autism-Specific Screening (Recommended at 18 and 24 Months)

The M-CHAT-R/F (Modified Checklist for Autism in Toddlers, Revised with Follow-Up) is a 20-item parent-completed questionnaire administered at 18 and 24 months (usable from 16-30 months). A score of 0-2 indicates low risk requiring no follow-up unless clinical concern exists. A score of 3-7 indicates medium risk, and the Follow-Up interview should be administered to reduce false positives. A score of 8-20 indicates high risk and warrants direct referral for evaluation. Sensitivity is approximately 85%, but positive predictive value is low (around 50%) without the Follow-Up component, which significantly reduces the false-positive rate.

Mental Health/Behavioral Screening

Depression screening with the PHQ-A begins at age 12 annually. The GAD-7 screens for anxiety in adolescents. The Pediatric Symptom Checklist (PSC) provides broad behavioral and emotional screening for ages 4-16. The CRAFFT screens for substance use in adolescents. The Edinburgh Postnatal Depression Scale screens for maternal depression at infant well-visits (1, 2, 4, and 6 month visits), recognizing that maternal depression directly affects infant development.

Vision Screening

From birth to 3 years, screening includes red reflex assessment, inspection, and cover-uncover testing. At 3-5 years, instrument-based screening (photoscreening or autorefractors) or optotype visual acuity (Lea symbols, HOTV) is used, with optotype testing beginning at 4 years. From age 5 onward, Snellen chart visual acuity is assessed annually.

Hearing Screening

Universal newborn hearing screening uses OAE or ABR. Pure-tone audiometry is performed at ages 4, 5, 6, 8, and 10 years. During adolescence, risk-based assessment continues at ages 11-14, 15-17, and 18-21 years.

Other Screening Tests

Anemia screening occurs at 12 months (hemoglobin or hematocrit) with risk-based screening thereafter. Lead screening is done at 12 and 24 months (risk-based, with universal screening in high-prevalence areas and for Medicaid-enrolled children). Universal non-fasting lipid panels are obtained at 9-11 years and 17-21 years. Blood pressure measurement begins annually at age 3 or earlier if risk factors exist. Oral health assessment includes fluoride exposure evaluation and dental referral by age 1 or first tooth eruption. STI screening for chlamydia, gonorrhea, and HIV is indicated in sexually active adolescents.

<image>Infographic of the AAP Bright Futures periodicity schedule showing well-child visit timing from birth to 21 years with icons indicating which screening tests (developmental, autism, vision, hearing, anemia, lead, lipid, depression) are recommended at each age</image>

Anticipatory Guidance Highlights by Age

Infancy (0-12 Months)

Key guidance includes safe sleep practices (ABCs), breastfeeding support, tummy time, rear-facing car seat safety, injury prevention, immunizations, avoiding screen time before 18 months, and dental care including no bottles in bed and fluoride varnish starting at tooth eruption.

Toddler/Preschool (1-5 Years)

Guidance focuses on limiting juice to 4 oz per day, transitioning to whole milk at 12 months (16-24 oz per day), water safety, poison prevention, firearm safety, screen time limits (1 hour per day of high-quality content for ages 2-5), toilet training readiness (usually 18-24 months), and establishing a dental home by age 1.

School-Age (6-12 Years)

Topics include seat belt use, bicycle helmet use, sports safety, healthy eating habits, daily physical activity (60 minutes), bullying assessment, internet safety, and puberty education beginning at 8-9 years.

Adolescence (13-21 Years)

Adolescent visits address the confidential HEEADSSS assessment, contraception and STI prevention, mental health and substance use screening, driving safety, concussion awareness, and transition planning to adult care for chronic conditions.

Developmental Surveillance vs. Screening

Surveillance (Every Visit)

Surveillance is an ongoing process of monitoring development through observation, milestone review, and eliciting parental concerns. It is flexible, clinical judgment-based, and captures concerns between formal screening intervals. It requires thorough knowledge of expected developmental milestones.

Screening (Specific Ages)

Screening involves administration of a validated, standardized tool with objective scoring and defined cutoff values. It addresses the critical limitation of surveillance alone, which misses approximately 70% of developmental delays. The AAP recommends formal screening at 9, 18, and 30 months plus autism-specific screening at 18 and 24 months.

When Screening is Positive

When a screening tool yields a positive result, the results should be discussed with the family, normalizing the process and emphasizing the benefits of early intervention. Referral for comprehensive developmental evaluation by a developmental pediatrician, child psychologist, or multidisciplinary team is indicated. Simultaneously, referral to Early Intervention (EI) should be made for children birth to 3 years, a state-funded program under IDEA Part C. Eligibility criteria vary by state (typically 25-50% delay in one or more domains), and services include speech therapy, occupational therapy, physical therapy, special instruction, and family support at no cost for evaluation. For children 3-5 years, referral to the school district for IDEA Part B preschool services is appropriate.

The critical principle is to avoid "wait and see" approaches. Developmental delays do not resolve with time, and early intervention significantly improves outcomes. Hearing and vision evaluation should always be part of any developmental delay workup.

Clinical Pearls

Formal developmental screening with a validated tool is more accurate than clinical judgment alone; studies demonstrate that clinician surveillance misses 70% of children with delays. Parents are excellent observers of their child's abilities, and parental concern should be treated as screening-positive until proven otherwise. The ASQ-3 can be completed in the waiting room, making it time-efficient for busy practices. Maternal depression screening at infant visits is effectively developmental screening for the child, as treating the mother protects the infant. A child who is not walking by 18 months or not speaking in 2-word phrases by 24 months needs immediate referral, not reassurance. The M-CHAT Follow-Up interview is essential because without it, the false-positive rate is unacceptably high and leads to unnecessary referrals.

Key Controversy: Universal Screening Effectiveness

Proponents argue that systematic screening identifies more children with delays, enables earlier intervention, and reduces disparities in identification. Critics note that screening tools have imperfect sensitivity and specificity, positive predictive value is modest (especially for autism), and there is insufficient evidence that universal screening improves long-term outcomes compared to targeted surveillance. The USPSTF in 2016 found insufficient evidence to recommend universal autism screening in children without clinical concerns (grade I). The AAP strongly disagrees with this assessment and continues to recommend universal screening at 18 and 24 months. Implementation barriers include time, cost, language barriers, electronic health record integration, and follow-up referral tracking.

References

• Hagan JF, Shaw JS, Duncan PM. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 4th Edition. AAP. 2017.
• Council on Children with Disabilities. Identifying Infants and Young Children with Developmental Disorders in the Medical Home. Pediatrics. 2006;118(1):405-420.
• Robins DL, et al. Validation of the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F). Pediatrics. 2014;133(1):37-45.
• Lipkin PH, Macias MM. Promoting Optimal Development: Identifying Infants and Young Children with Developmental Disorders Through Developmental Surveillance and Screening. Pediatrics. 2020;145(1):e20193449.
• Siu AL, USPSTF. Screening for Autism Spectrum Disorder in Young Children. JAMA. 2016;315(7):691-696.
• Squires J, Bricker D. Ages and Stages Questionnaires, Third Edition (ASQ-3). Brookes Publishing. 2009.

Read this lecture as Markdown